Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
По алфавиту
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- L
- M
- N
- O
- P
- Q
- R
- S
- T
- V
- W
- X
- Y
- Z
- І
- А
- Б
- В
- Г
- Д
- Е
- Ж
- З
- И
- К
- Л
- М
- Н
- О
- П
- Р
- С
- Т
- У
- Ф
- Х
- Ц
- Ч
- Ш
- Щ
- Э
- Ю
- Я
- Весь список
Warning: mb_strpos(): Empty delimiter in /var/www/u1363561/data/www/biotech.spb.ru/wp-content/plugins/code-snippets/php/snippet-ops.php(581) : eval()’d code(4) : eval()’d code on line 13
B Göhring, D Riemann, U Rebmann, H Heynemann, J Schabel, J Langner
Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FUUrol Res. 1996;24(5):297-303.
Baer M.R., George S.L., Caligiuri M.A. et al.
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.J Clin Oncol. 2008 Oct 20;26(30):4934-9. doi: 10.1200/JCO.2008.17.0472. Epub 2008 Jun 30.
Bauer D, Wasmuth S, Hermans P. et al.
On the influence of neutrophils in corneas with necrotizing HSV-1 keratitis following amniotic membrane transplantation.Exp Eye Res. 2007 Sep;85(3):335-45. Epub 2007 Jun 14.
Belyakova K.L., Stepanova O.I., Sheveleva A.R. et al. 
PDF
Interaction of NK Cells, Trophoblast, and Endothelial Cells during Angiogenesis.
Cell Technologies in Biology and Medicine. — No. 1, May. — 2019. — P. 169-176.
Bendickova K., Fric J. PDF
J Leukoc Biol. 2020 Jul; 108(1): 427–437.
Berezhko V., Rudneva О., Uspensky V. , Sasikova R.
Иммуномодуляторы в комплексе с антигеном из протосколексов echinococcus multilocularis в профилактике экспериментального альвеолярного эхинококкоза.Meditsinskaia parazitologiia i parazitarnye bolezni. – 2017.08.20.
Bert W O’Malley Jr, Daqing Li, Shelly J McQuone, Robert Ralston
Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedsideLaryngoscope. 2005 Mar;115(3):391-404.
Beverly J Lange, Richard K Yang, Jacek Gan, Jaquelyn A Hank, Eric L Sievers, Todd A Alonzo, Robert B Gerbing, Paul M Sondel
Soluble interleukin-2 receptor α activation in a Children’s Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemiaPediatr Blood Cancer. 2011 Sep;57(3):398-405.
Boldt DH, Mills BJ, Gemlo BT et al.
Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.Cancer Res. 1988 Aug 1;48(15):4409-16. PMID: 3260537.
Boubnova N., Smirnov M., Petrov S.
Clinical application of Roncoleukin® (interleukin-2).
Abstacts book of 5th Sci. Meeting of Europ. Soc. of chemotherapy inf. diseases. S.-Petersburg, 1997. P. 36 (B016).
Brendan Curti, Gregory A Daniels, David F McDermott, Joseph I Clark, Howard L Kaufman, Theodore F Logan, Jatinder Singh, Meenu Kaur, Theresa L Luna, Nancy Gregory, Michael A Morse, Michael K K Wong, Janice P Dutcher
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM SM registryJ Immunother Cancer. 2017 Dec 19;5(1):102.
Bukhtoyarov O., Samarin D. PDF
European Journal of Medical and Health Sciences. — Vol 3, Issue 4, July 2021.
Buyse M., Squifflet P., Lange B.J. et al.
Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.Blood (2011) 117 (26): 7007-7013.
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.